USA flag logo/image

An Official Website of the United States Government

Novel Thermal Transcervical Sterilization Device

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
79878
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
HD047063
Solicitation Year:
N/A
Solicitation Topic Code:
NICHD
Solicitation Number:
N/A
Small Business Information
NOVOMEDICS, LLC
1522 Timber Creek Dr. Missouri City, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: Novel Thermal Transcervical Sterilization Device
Agency: HHS
Contract: 2R44HD047063-02A2
Award Amount: $780,489.00
 

Abstract:

DESCRIPTION (provided by applicant): A safe and reliable procedure to perform transcervical sterilization could replace laparoscopic tubal ligation - the most popular permanent birth control method. Over 700,000 American women are expected to receive the t ubal surgery this year. The transcervical approach offers a significant improvement because it shortens recovery for the patient and increases practice efficiency for the physician by making an office-based sterilization procedure feasible. Novomedics' tra nscervical procedure takes advantage of the body's natural healing effects to scare off the fallopian tube. Our approach uses a proprietary thermal catheter to treat a sufficient amount of the tubal lumen. Pilot in vivo and survival data with an early prot otype have demonstrated effective and reliable tubal occlusion in two weeks without leaving any foreign materials in the fallopian tube. In addition, pilot human safety data has also been obtained. In the proposed Phase II program, we will incorporate nove l safety features demonstrated in Phase I and strengthen the design and quality of the NovoSeal system to be ready for large scale clinical evaluation in Phase III. The end result of this effort will be a new technology for safe and effective transcervical female sterilization: Specific Aim 1. Evaluation of NovoSeal catheter system and treatment method in freshly extirpated human and animal reproductive tissue in preparation for quantitative in vivo preclinical and clinical studies. Specific Aim 2. In vivo characterization of the NovoSeal catheter and treatment method in an established animal model. Specific Aim 3. In vivo characterization of the NovoSeal catheter and treatment method in human reproductive tissue during peri-hysterectomy surgery. Specific Ai m 4. A pilot study for in vivo characterization of the NovoSeal catheter and treatment method in human pre-hysterectomy patients. PUBLIC HEALTH RELEVANCE: Project Narrative The clinical practice of transcervical sterilization is growing and Novomedi cs' proposed technology has numerous advantages over current product offerings. Our technology solves problems with previous thermal approaches and will offer physicians a simple, cost effective, and efficient method for achieving permanent sterilization w ithout the requirement of a surgical procedure or the use of implants. The commercial potential for such a technology is without doubt very large, especially in light of the increased patient benefits of avoiding invasive surgery as well as the time and co nvenience to physicians who use the technology for an office-based sterilization procedure.

Principal Investigator:

Eric K. Chan
2815342378
EKCHAN@NOVOMEDICS.COM

Business Contact:

Eric K. Chan
ekchan@novomedics.com
Small Business Information at Submission:

NOVOMEDICS, LLC
NOVOMEDICS, LLC 1522 Timber Creek Dr. Missouri City, TX -

EIN/Tax ID: 176053000
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No